and specifi city of ASDAS cut-off values for disease activity states

Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies

Achievement rate and predictive factors of the recommended therapeutical target in patients with axial spondyloarthritis who remain on biological therapy: a prospective cohort study in Spain

and specifi city of ASDAS cut-off values for disease activity states

JPM, Free Full-Text

Current health resources required for the management of ankylosing spondylitis in developing areas of China

Recommendations by the Spanish Society of Rheumatology on the Use of Biological Therapies in Axial Spondyloarthritis

Cureus, The Long-Term Effects of Short-Period Adalimumab Biosimilar Usage in Ankylosing Spondylitis

ASAS on X: The Ankylosing Spondylitis Disease Activity Score (ASDAS) is the recommended instrument in axial SpA / X

A simplified version of Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with ankylosing spondylitis

Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies - The Lancet Rheumatology